Literature DB >> 22359395

Detection of myo-inositol trispyrophosphate in equine urine and plasma by hydrophillic interaction chromatography-tandem mass spectrometry.

April S Y Wong1, Emmie N M Ho, Terence S M Wan.   

Abstract

Myo-inositol trispyrophosphate (ITPP) is a new drug capable of increasing the amount of oxygen in hypoxic tissues. Studies have shown that administration of ITPP increases the maximal exercise capacity in normal mice as well as mice with severe heart failure. The properties of ITPP make it an ideal candidate as a doping agent to enhance performance in racehorses. While there have been speculations in the horseracing industry that the covert use of ITPP is already widespread, no reported method exists for the detection of ITPP in equine biological samples. ITPP is a difficult-to-detect drug due to its hydrophilic nature; the complexity of equine biological matrices also adds to the problem. This paper describes for the first time a method for the detection and confirmation of ITPP in equine urine and plasma. ITPP was isolated from the sample matrices by solid-phase extraction and the extract was analyzed by hydrophilic interaction chromatography-tandem mass spectrometry. ITPP could be detected at low ppb levels in both fortified equine plasma and urine with good precision, fast instrumental turnaround time, and negligible matrix interferences. To our knowledge, this is the first report of a validated method for the detection and unequivocal confirmation of low levels of ITPP in any biological fluid.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22359395     DOI: 10.1002/dta.397

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  1 in total

1.  Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.

Authors:  Perparim Limani; Michael Linecker; Philipp Kron; Panagiotis Samaras; Bernhard Pestalozzi; Roger Stupp; Alexander Jetter; Philipp Dutkowski; Beat Müllhaupt; Andrea Schlegel; Claude Nicolau; Jean-Marie Lehn; Henrik Petrowsky; Bostjan Humar; Rolf Graf; Pierre-Alain Clavien
Journal:  BMC Cancer       Date:  2016-10-19       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.